{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:55:19Z","timestamp":1790276119998,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,1,31]],"date-time":"2002-01-31T00:00:00Z","timestamp":1012435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>This Phase II study assessed the response rate and toxicity profile of the combination CPT\u201011 and cisplatin administered weekly to patients with untreated, advanced adenocarcinoma of the stomach or the gastroesophageal junction.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with histologic proof of adenocarcinoma of the stomach or the gastroesophageal junction with adequate liver, kidney, and bone marrow functions were treated with 65 mg\/m<jats:sup>2<\/jats:sup> CPT\u201011 plus 30 mg\/m<jats:sup>2<\/jats:sup> cisplatin, both administered intravenously 1 day per week for 4 consecutive weeks, followed by a recovery period of 2 consecutive weeks. The response rate, time to disease progression, survival, and toxic effects were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Thirty\u2010six of 38 registered patients (95%) were assessable. The median number of 6\u2010week cycles per patient was 2.5 (range, 1\u20137 6\u2010week cycles). Four patients (11%) achieved a complete response, and 17 patients (47%) had a partial response for an overall response rate of 58%. The median time to progression of carcinoma was 24 weeks, and the median survival was 9 months (range, 1\u201323+ months). There was one treatment\u2010related death. Major toxic effects included diarrhea, neutropenia, and fatigue. Ninety percent of all planned doses were delivered on time; however, 53 of 79 canceled or delayed weekly doses (66%) occurred in the third or fourth week of the therapy cycle.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The combination of CPT\u201011 and cisplatin is active against gastric or gastroesophageal adenocarcinoma and needs to be studied further. A modification in doses and schedules may be warranted to make the regimen more tolerable to patients. The addition of other active drugs or radiation therapy to this regimen would be of interest. Cancer 2002;94:641\u20136. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10279<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10279","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T00:51:41Z","timestamp":1030236701000},"page":"641-646","source":"Crossref","is-referenced-by-count":121,"title":["CPT\u201011 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma"],"prefix":"10.1002","volume":"94","author":[{"given":"Jaffer A.","family":"Ajani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W. T.","family":"Pisters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry W.","family":"Feig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chusilp","family":"Charnsangavej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,31]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.49.1.33"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P"},{"key":"e_1_2_5_4_2","first-page":"12","article-title":"A randomized, Phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non\u2010resectable gastric cancer","volume":"3","author":"Pyrhonen S","year":"1992","journal-title":"Ann Oncol"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058778"},{"key":"e_1_2_5_6_2","unstructured":"ScheithauerW KomekG ZehB et al.Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer. A randomized trial[abstract]. Second International Conference on Biology Prevention and Treatment of GI Malignancy Koln Germany.1995:68."},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.1985.03350380077025","article-title":"A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin and mitomycin","volume":"253","author":"Cullinan SA","year":"1985","journal-title":"JAMA"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3858"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909009017560"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_5_11_2","first-page":"198","article-title":"A late Phase II study of irinotecan (CPT\u201011) in patients with advanced gastric cancers","volume":"12","author":"Kambe M","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_12_2","first-page":"258a","article-title":"Final results of a Phase II trial of CPT\u201011 in patients with advanced gastric cancer","volume":"18","author":"Kohne CH","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.921"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.319"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3270"},{"key":"e_1_2_5_16_2","first-page":"262a","article-title":"A Phase II study of S\u20101 in patients with advanced gastric cancer","volume":"17","author":"Ohtsu A","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_17_2","first-page":"262a","article-title":"Late Phase II study of S\u20101, a novel oral fluoropyrimidine derivative, in patients with advanced gastric cancer","volume":"17","author":"Kurihara M","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_5_18_2","first-page":"134a","article-title":"Irinotecan in combination with CDDP or 5\u2010FU and folinic acid is active in patients with advanced gastric or gastroesophageal junction adenocarcinoma: final results of a randomized Phase II study","volume":"20","author":"Pozzo C","year":"2001","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10279","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:10:08Z","timestamp":1760278208000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10279"}},"subtitle":["Results of a Phase II study"],"short-title":[],"issued":{"date-parts":[[2002,1,31]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["10.1002\/cncr.10279"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10279","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1,31]]}}}